Clinical Trials Logo

Filter by:
NCT ID: NCT02818868 Completed - Ischemic Stroke Clinical Trials

Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis Trial

ALVO
Start date: July 2016
Phase:
Study type: Observational

The aim of this study is to investigate the clinical events of the patients with acute cerebral large vessel occlusion or stenosis and atrial fibrillation, treated by apixaban within 14 days after onset. This is the observational study that patients will be made the registration at the timing of both retrospective period and prospective period.

NCT ID: NCT02815644 Completed - Healthy Clinical Trials

Empa/Lina FDC Food Effect Study (Japan)

Start date: July 15, 2016
Phase: Phase 1
Study type: Interventional

The trial will be performed as an open-label, randomised, single-dose, two-sequence crossover design for the assessment of effect of food on bioavailability of empagliflozin / linagliptin fixed dose combination (FDC) tablet.

NCT ID: NCT02812706 Completed - Multiple Myeloma Clinical Trials

Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients

Islands
Start date: September 5, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Primary Objectives: - Phase I: To evaluate safety and tolerability of isatuximab in Japanese participants with relapsed and refractory multiple myeloma. - Phase II: To evaluate efficacy of isatuximab at recommended dose and to further evaluate the overall response rate (ORR) of isatuximab in Japanese participants with relapsed and refractory multiple myeloma. Secondary Objectives: - To evaluate the safety including immunogenicity of isatuximab. The severity, frequency and incidence of all adverse events were assessed. - To evaluate the pharmacokinetic (PK) profile of isatuximab in the proposed dosing schedule. - To assess the efficacy using International Myeloma Working Group (IMWG) uniform response criteria. - To assess the relationship between Baseline cluster of differentiation 38 (CD38) receptor density on multiple myeloma cells and efficacy.

NCT ID: NCT02811302 Completed - Clinical trials for Respiratory Depression

PRediction of Opioid-induced Respiratory Depression In Patients Monitored by capnoGraphY

PRODIGY
Start date: April 7, 2017
Phase: N/A
Study type: Interventional

PRODIGY is a prospective, multi-center, post-market, international cohort study. The primary objective of this study is to derive a score to identify subjects at risk to have respiratory depression (RD) episodes in patients undergoing opioid therapy in the hospital ward and monitored by capnography. The score will be derived by using subjects within the derivation cohort and internally validated using subjects within the validation cohort. The primary endpoint used to derive the score will be the occurrence of RD episodes derived by Capnostream 20p device memory data combined with clinical data and validated by an independent Clinical Endpoint Committee (CEC) during the study course.

NCT ID: NCT02810457 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer

AVANA
Start date: September 7, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer

NCT ID: NCT02809105 Completed - Clinical trials for Chronic Constipation

A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation

Start date: June 24, 2016
Phase: Phase 3
Study type: Interventional

The objective of this study is to verify the efficacy and investigate the safety of the study drug when ASP0456 is administered orally for 4 weeks and 52 weeks.

NCT ID: NCT02808403 Completed - Clinical trials for Hypercholesterolemia

Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan

Start date: June 24, 2016
Phase:
Study type: Observational

The purpose of this post-marketing survey is to obtain real-world information on the safety and effectiveness of evolocumab in Japan.

NCT ID: NCT02808026 Completed - Severe Hypertension Clinical Trials

Study of CS-3150 in Patients With Severe Hypertension

Start date: June 2016
Phase: Phase 3
Study type: Interventional

To examine antihypertensive effect and safety of administration of CS-3150 in patients with severe hypertension (Grade III).

NCT ID: NCT02807987 Completed - Clinical trials for Hypertension With Moderate Renal Impairment

Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment

Start date: June 2016
Phase: Phase 3
Study type: Interventional

To examine antihypertensive effect and safety of administration of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with moderate renal impairment.

NCT ID: NCT02807974 Completed - Hypertension Clinical Trials

Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria

Start date: June 2016
Phase: Phase 3
Study type: Interventional

To examine antihypertensive effect and safety of administration of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with type 2 diabetes and albuminuria.